atorvastatin has been researched along with Hypoxia in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Li, S; Liu, Q; Liu, S; Mu, D; Qu, Y; Su, X; Sun, H; Ying, J; Yu, L; Zhao, F; Zhou, R | 1 |
| Hou, Y; Nie, X; Ren, J; Tang, T; Wang, Y; Zhao, Y | 1 |
| Chen, Y; Chen, YY; Cheng, HJ; Chiu, KY; Yuan, YT; Zeng, HQ; Zhang, XB | 1 |
| Hu, Y; Jin, M; Li, GC; Liu, HG; Liu, W; Ren, J; You, ZX | 1 |
| Du, J; Meng, X; Wang, J; Wang, R; Xie, H; Zhou, Z; Zhu, Y | 1 |
| Abdallah, D; El-Ganainy, SO; El-Khatib, AS; El-Mallah, A; Khattab, MM; Mohy El-Din, MM | 1 |
| Baldazza, M; Cachot, S; Faury, G; Fhayli, W; Joyeux-Faure, M; Korichneva, I; Lévy, P; Pépin, JL; Ribuot, C; Totoson, P | 1 |
| Chen, P; Dai, L; Wu, S; Zhang, Y; Zhao, S | 1 |
| Deng, Y; Guo, X; Liu, H; Shang, J; Yuan, X; Zhu, D | 1 |
| Deng, Y; Guo, XL; Liu, HG; Pan, YY; Yuan, X; Zhu, D | 1 |
| Cheng, WP; Chua, SK; Lo, HM; Lu, MJ; Shyu, KG; Wang, BW | 1 |
| Dai, L; Wu, S | 1 |
| Chiu, CZ; Shyu, KG; Wang, BW | 1 |
| Balla, J; Dorosz, J; Dulak, J; Jazwa, A; Jozkowicz, A; Loboda, A; Molema, G | 1 |
| Harten, SK; Haskard, DO; Johns, M; Kinderlerer, AR; Lidington, EA; Mason, JC; Maxwell, PH; Steinberg, R | 1 |
| Frøbert, O; Holmager, P; Jensen, KM; Schmidt, EB; Simonsen, U | 1 |
1 trial(s) available for atorvastatin and Hypoxia
| Article | Year |
|---|---|
Effect of acute changes in oxygen tension on flow-mediated dilation. Relation to cardivascular risk.
Topics: Administration, Inhalation; Adult; Atorvastatin; Brachial Artery; Cardiovascular Diseases; Cholesterol; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperoxia; Hypoxia; Lipoproteins; Male; Middle Aged; Nitroglycerin; Oxygen; Pyrroles; Regional Blood Flow; Research Design; Risk Factors; Treatment Outcome; Triglycerides; Ultrasonography; Vasoconstriction; Vasodilation; Vasodilator Agents | 2008 |
15 other study(ies) available for atorvastatin and Hypoxia
| Article | Year |
|---|---|
Atorvastatin inhibits neuronal apoptosis via activating cAMP/PKA/p-CREB/BDNF pathway in hypoxic-ischemic neonatal rats.
Topics: Animals; Animals, Newborn; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Brain-Derived Neurotrophic Factor; Caspase 3; Cerebral Infarction; Hypoxia; Hypoxia-Ischemia, Brain; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley | 2022 |
Hypoxia aggravates the burden of yellowstripe goby (Mugilogobius chulae) under atorvastatin exposure.
Topics: Animals; Aquatic Organisms; Atorvastatin; Fishes; Hypoxia; Perciformes; Water Pollutants, Chemical | 2023 |
Atorvastatin attenuates intermittent hypoxia-induced myocardial oxidative stress in a mouse obstructive sleep apnea model.
Topics: Animals; Apoptosis; Atorvastatin; Disease Models, Animal; Heart; Hypoxia; Male; Mice; Mice, Inbred C57BL; Myocardial Ischemia; NF-E2-Related Factor 2; Oxidative Stress; Sleep Apnea, Obstructive | 2021 |
Atorvastatin Attenuates Myocardial Hypertrophy Induced by Chronic Intermittent Hypoxia In Vitro Partly through miR-31/PKCε Pathway.
Topics: Animals; Atorvastatin; Cardiomegaly; Cardiotonic Agents; Cell Line; Chronic Disease; Hypoxia; MicroRNAs; Myocardium; Myocytes, Cardiac; Protein Kinase C-epsilon; Rats; Signal Transduction; Up-Regulation | 2018 |
Atorvastatin attenuates paraquat poisoning-induced epithelial-mesenchymal transition via downregulating hypoxia-inducible factor-1 alpha.
Topics: A549 Cells; Animals; Atorvastatin; Cadherins; Cell Line; Epithelial-Mesenchymal Transition; Humans; Hypoxia; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Lung; Lung Injury; Male; Paraquat; Pulmonary Fibrosis; Rats; Rats, Sprague-Dawley; Signal Transduction; Zonula Occludens-1 Protein | 2018 |
A novel investigation of statins myotoxic mechanism: effect of atorvastatin on respiratory muscles in hypoxic environment.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Hypoxia; Male; Muscle Contraction; Muscle, Skeletal; Rats; Rats, Sprague-Dawley; Ubiquinone | 2019 |
Atorvastatin protects against deleterious cardiovascular consequences induced by chronic intermittent hypoxia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Disease Models, Animal; Heptanoic Acids; Hypoxia; Oxidative Stress; Pyrroles; Rats; Treatment Outcome | 2013 |
Atorvastatin attenuates involvement of RhoA/Rho-kinase pathway and NF-κB activation in hypoxic pulmonary hypertensive rats.
Topics: Animals; Atorvastatin; Blotting, Western; Heptanoic Acids; Hypertension, Pulmonary; Hypoxia; Male; NF-kappa B; Pyrroles; Random Allocation; Rats; Rats, Wistar; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction | 2014 |
Atorvastatin attenuates myocardial remodeling induced by chronic intermittent hypoxia in rats: partly involvement of TLR-4/MYD88 pathway.
Topics: Animals; Atorvastatin; Cardiomegaly; Cytokines; Heart; Heptanoic Acids; Hypoxia; Male; Myeloid Differentiation Factor 88; Myocardium; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Reactive Oxygen Species; RNA, Messenger; Signal Transduction; Sleep Apnea, Obstructive; Toll-Like Receptor 4; Ventricular Remodeling | 2014 |
Efficacy of atorvastatin on hippocampal neuronal damage caused by chronic intermittent hypoxia: Involving TLR4 and its downstream signaling pathway.
Topics: Animals; Atorvastatin; Chronic Disease; Disease Models, Animal; Hippocampus; Hypoxia; Interleukin-1beta; Male; Malondialdehyde; Mice, Inbred C57BL; Myeloid Differentiation Factor 88; Neurons; Neuroprotective Agents; Random Allocation; Signal Transduction; Sleep Apnea, Obstructive; Superoxide Dismutase; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2015 |
Atorvastatin alleviates cardiomyocyte apoptosis by suppressing TRB3 induced by acute myocardial infarction and hypoxia.
Topics: Animals; Apoptosis; Atorvastatin; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia; Myocardial Infarction; Myocytes, Cardiac; Protein Serine-Threonine Kinases; Rats; Rats, Wistar | 2017 |
[Atorvastatin attenuates hypoxic pulmonary hypertension in rats by inhibiting RhoA/Rho kinase pathway].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Hemodynamics; Heptanoic Acids; Hypertension, Pulmonary; Hypoxia; Male; Pulmonary Artery; Pyrroles; Random Allocation; Rats; Rats, Wistar; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Ventricular Remodeling | 2011 |
Use of atorvastatin to inhibit hypoxia-induced myocardin expression.
Topics: Animals; Animals, Newborn; Atorvastatin; Blotting, Western; Cells, Cultured; Electrophoretic Mobility Shift Assay; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy; Hypoxia; Myocytes, Cardiac; Nuclear Proteins; Pyrroles; Rats; Rats, Wistar; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Trans-Activators | 2012 |
Atorvastatin prevents hypoxia-induced inhibition of endothelial nitric oxide synthase expression but does not affect heme oxygenase-1 in human microvascular endothelial cells.
Topics: Atherosclerosis; Atorvastatin; Blotting, Western; Cells, Cultured; Endothelium, Vascular; Gene Expression Regulation, Enzymologic; Heme Oxygenase-1; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoxia; Microcirculation; Nitric Oxide Synthase Type III; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Atorvastatin; CD55 Antigens; CD59 Antigens; Cells, Cultured; Cobalt; Cytoprotection; Deferoxamine; Diterpenes; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia; Iron Chelating Agents; Mevalonic Acid; Pyrroles; RNA, Messenger; Up-Regulation | 2006 |